NCT06427005View on ClinicalTrials.gov

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

August 18, 2025

Study Completion Date

April 30, 2026

Conditions
FruquintinibS-1Raltitrexed
Interventions
DRUG

Fruquintinib

Fruquintinib 5 mg daily for 14 days followed by a 7-day break

DRUG

S-1

S-1 80-120 mg daily for 14 days, followed by a 7-day break

DRUG

raltitrexed

raltitrexed 3 mg/m² on day 1, with a maximum dose of 5 mg

Trial Locations (2)

610044

RECRUITING

Sichuan University West China Hospital, Chengdu

Unknown

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
collaborator

Beijing Xisike Clinical Oncology Research Foundation

UNKNOWN

lead

Meng Qiu

OTHER